^
    6d
    SL03-OHD-104: Phase 1 Study of Shattuck Labs (SL)-172154 in Subjects With MDS or AML (clinicaltrials.gov)
    P1, N=106, Terminated, Shattuck Labs, Inc. | Completed --> Terminated; Development discontinued
    Trial termination
    |
    TP53 (Tumor protein P53)
    |
    TP53 mutation
    |
    Venclexta (venetoclax) • azacitidine • SL-172154
    17d
    Phase I/II clinical trial of a melanoma vaccine targeting shared non-mutated antigens and a shared mutated BRAF neoantigen with an agonistic CD40 antibody (CDX-1140) plus TLR3 agonist (poly-ICLC). (PubMed, J Immunother Cancer)
    The vaccine was safe, well-tolerated, and immunogenic. Optimization of vaccines that include agonistic CD40 antibody is needed to enhance immunogenicity. Induction of a multifunctional CD4+ T cell response to mBRAF supports targeting shared mutated neoantigens with melanoma vaccines.
    P1/2 data • Journal • IO biomarker • First-in-human
    |
    BRAF (B-raf proto-oncogene) • CD8 (cluster of differentiation 8) • LAMP3 (Lysosomal Associated Membrane Protein 3) • CD40 (CD40 Molecule)
    |
    BRAF V600E • BRAF mutation • BRAF V600
    |
    CDX-1140 • Hiltonol (poly-ICLC)
    18d
    IGNITE: Maintenance Combinatorial Myeloid Immunotherapy for Unresectable Pancreatic Cancer (clinicaltrials.gov)
    P2, N=100, Recruiting, University of Pennsylvania | Trial completion date: Aug 2027 --> Dec 2028 | Trial primary completion date: Feb 2026 --> Oct 2027
    Trial completion date • Trial primary completion date
    |
    Imprime PGG (odetiglucan) • mitazalimab (ADC-1013)
    25d
    CROCOBIL: Testing Mitazalimab in Combination With Standard Chemotherapy in Immunotherapy Resistant Advanced Biliary Tract Cancers (clinicaltrials.gov)
    P2/3, N=160, Not yet recruiting, UNICANCER
    New P2/3 trial
    |
    5-fluorouracil • oxaliplatin • leucovorin calcium • mitazalimab (ADC-1013)
    1m
    Phase I Study of APX005M in Pediatric Central Nervous System Tumors (clinicaltrials.gov)
    P1, N=32, Active, not recruiting, Pediatric Brain Tumor Consortium | Trial completion date: Nov 2025 --> Jun 2026
    Trial completion date
    |
    TMB (Tumor Mutational Burden) • CD4 (CD4 Molecule)
    |
    sotigalimab (PYX-107)
    2ms
    Phase I clinical study evaluating the safety, tolerability, pharmacokinetic characteristics, and preliminary efficacy of LNF1901 in the treatment of advanced malignant tumor patients (ChiCTR2500111722)
    P1, N=82, Recruiting, Sun Yat-sen University Cancer Center; Sun Yat-sen University Cancer Center
    New P1 trial
    2ms
    Personalized Peptide Vaccine in Treating Patients With Advanced Pancreatic Cancer or Colorectal Cancer (clinicaltrials.gov)
    P1, N=117, Active, not recruiting, M.D. Anderson Cancer Center | Enrolling by invitation --> Active, not recruiting
    Enrollment closed
    |
    CA 19-9 (Cancer antigen 19-9)
    |
    Keytruda (pembrolizumab) • Zyclara (imiquimod) • sotigalimab (PYX-107)
    2ms
    A Study of KK2269 in Adult Participants With Solid Tumors (clinicaltrials.gov)
    P1, N=101, Recruiting, Kyowa Kirin Co., Ltd. | N=71 --> 101 | Trial completion date: Dec 2027 --> Mar 2029 | Trial primary completion date: Dec 2027 --> Mar 2029
    Enrollment change • Trial completion date • Trial primary completion date • First-in-human
    |
    docetaxel
    2ms
    CAR-T triggers TAM reeducation and adaptive anti-tumor response via TREM2 deficiency or CD40 agonist. (PubMed, Cell Rep Med)
    Notably, the clinical agonist sotigalimab similarly enhances human CD8+ T cell migration in vitro. Our findings highlight the significance of combining GPC3-CAR-T therapy with CD40 agonist as a critical pre-requisite for eliciting reeducation of TAMs and enhancing the efficacy of CAR-T therapy in HCC.
    Journal • IO biomarker
    |
    CD8 (cluster of differentiation 8) • CXCL9 (Chemokine (C-X-C motif) ligand 9) • STAT1 (Signal Transducer And Activator Of Transcription 1) • CD40 (CD40 Molecule) • TREM2 (Triggering Receptor Expressed On Myeloid Cells 2)
    |
    sotigalimab (PYX-107)
    2ms
    FORTRESS: NG-350A Plus Chemoradiotherapy for Locally Advanced Rectal Cancer (clinicaltrials.gov)
    P1, N=30, Recruiting, Akamis Bio | Trial completion date: May 2028 --> Nov 2028 | Trial primary completion date: May 2026 --> Nov 2026
    Trial completion date • Trial primary completion date
    |
    capecitabine • NG-350A
    2ms
    TACTIC: MP0317 in Combination With Chemoimmunotherapy in First Line Treatment for Patients With Advanced Biliary Tract Carcinoma (clinicaltrials.gov)
    P2, N=75, Recruiting, Centre Hospitalier Universitaire de Besancon | Not yet recruiting --> Recruiting | Trial completion date: Jun 2029 --> Nov 2029 | Initiation date: Jun 2025 --> Dec 2025 | Trial primary completion date: Jun 2028 --> Nov 2028
    Enrollment open • Trial completion date • Trial initiation date • Trial primary completion date
    |
    cisplatin • Imfinzi (durvalumab) • gemcitabine • MP0317
    2ms
    A Study of ABBV-927 and ABBV-181, an Immunotherapy, in Participants With Advanced Solid Tumors (clinicaltrials.gov)
    P1, N=163, Active, not recruiting, AbbVie | Trial completion date: Mar 2026 --> Sep 2026 | Trial primary completion date: Mar 2026 --> Sep 2026
    Trial completion date • Trial primary completion date
    |
    budigalimab (ABBV-181) • giloralimab (ABBV-927)